Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05902494 · ClinicalTrials.gov registry record
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
A clinical trial, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 389
- Enrollment target
NCT05902494 is a clinical trial that has completed, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 389 participants.
The verdict
NCT05902494 has completed, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 389 participants
- Enrollment target
Study Summary
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2025-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05902494
The ClinicalTrials.gov registry entry for NCT05902494 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05902494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05902494 about?
NCT05902494 is a clinical study titled "HER2 and LA/mUC: A Multi-country Chart Review Cohort Study". This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have uroth...
What is the current status of trial NCT05902494?
This trial is currently completed. The enrollment target is 389 participants. The study started on 2023-06-29. Estimated completion is 2025-06-18.
Who is sponsoring clinical trial NCT05902494?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.